The Technical Analyst
Select Language :

Chiasma, Inc. [CHMA]

Exchange: Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Chiasma, Inc. is listed at the NASDAQ Exchange

-6.00% $3.76

Last updated: 21 Jan 2022 @ 12:02 pm


FUNDAMENTALS
MarketCap: 237.81 mill
EPS: -1.573
P/E: 0.000
Earnings Date: Mar 02, 2022
SharesOutstanding: 63.25 mill
Avg Daily Volume: 0.996 mill
RATING 2021-09-15
B+
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/191/202/203/204/201/21
Revenuen/an/an/an/a
Gr.Profitn/an/an/an/a
Ebit
Asset
Debtn/an/an/a
DISCOUNTED CASH FLOW VALUE
$4.06
(7.87%) $0.296
Date: 2022-01-21

Insider Trading

Date Person Action Amount type
2021-08-05 Minick Scott Sell 87 194 Common Stock
2021-08-05 Kannan Raj Sell 137 095 Common Stock
2021-08-05 Foley Todd Sell 10 000 Stock Option (Right to Buy)
2021-08-05 Enamait Drew Sell 16 700 Stock Option (Right to Buy)
2021-08-05 Doyle John Brendan Sell 175 000 Stock Option (Right to Buy)
INSIDER POWER
-61.81
Last 100 transactions
Buy: 4 128 022 | Sell: 8 155 316

Forecast: 13:42 - $3.76

Live Trading Signals (every 1 min)

Forecast 1: 12:12 - $3.76
Forecast 2: 13:02 - $3.76
Forecast 3: 13:42 - $3.76
SCORE
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.76 (-6.00% )
Volume 8.20 mill
Avg. Vol. 0.996 mill
% of Avg. Vol 822.65 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Chiasma, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Chiasma, Inc.

RSI

Intraday RSI14 chart for Chiasma, Inc.
The Live Chart for Chiasma, Inc.
Profile picture for
            Chiasma, Inc.

CHMA

Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Last 10 Buy Signals
Date Signal @
HTLFJan 21 - 16:44$51.85
SEIIJan 21 - 16:44$0.0095
CIHJan 21 - 16:43$1.110
ADVJan 21 - 16:43$6.99
BANRJan 21 - 16:43$64.74
NTWKJan 21 - 16:43$3.95
CVETJan 21 - 16:43$18.23
LBPSJan 21 - 16:42$4.54
MNTXJan 21 - 16:43$6.10
MFHJan 21 - 16:43$2.70

Stock Peers

Company Price Change
CHMA3.76-6.00%
ADMS8.220.00%
CABA2.88-3.68%
CODX7.77-5.93%
GALT1.934-4.72%
IMNM7.80-10.86%
OVID3.12-0.80%
PLXP5.97-3.08%
SRRA18.16-3.61%
VINC7.002.94%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.